Cephalon on hold by Jefferies

Jefferies & Co., Inc. analyst David Windley rated Cephalon, Inc. at hold on news of the company's "excellent run" during the month of October that coincided with rising expectations for Fentora. Windley's revised target is $61.50, with sales and earnings per share forecasts for the September quarter of $425 million and $1.17, respectively. Shares of the Frazer, Pa.-based pharmaceutical company were down 24 cents, or 0.34%, at $69.94. (Nasdaq: CEPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.